
|Articles|November 3, 2015
ICON Partners with iCardiac On Phase I
Advertisement
ICON announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. More accurate early QT studies may eliminate the need for later stage TQT studies, potentially saving costs.
Read
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
Breaking the Efficacy Ceiling in IBD and Beyond
4
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
5




